Viva Engage helps Firstline Workers improve customer service and provide valuable perspectives to the entire organization.
摘要: Reports that US President Bill Clinton vetoed an item that would have allowed New York State to continue taxing healthcare providers in the state. State government's criticism of the veto; Plans of pursuing the overturn of the veto; Benefits to managed care providers in the state....
“Although we have these amazing trials where we’re giving free drugs to our patients and proving that we have these huge survival benefits, if when these drugs come to market, they are so expensive and the co-pays are so high that the patients who have cancer cannot actually get the...
Thus, routine use of the test may lead to inequitable access to the healthcare. Overall, the Guideline Development Group (GDG) concluded that the benefits of using AST to guide the therapy can outweigh the potential adverse effects and that its use should be encouraged at least in people on...
Eisai’s Corporate Concept is to “give first thought to patients and the people in the daily living domain, and [to] increase the benefits that healthcare provides.” Under this Concept [also known ...
Pupillary dilation may occur due to the anticholinergic effects of Cobenfy. This may trigger an acute angle closure attack in patients with anatomically narrow angles. In patients known to have anatomically narrow angles, Cobenfy should only be used if the potential benefits outweigh the risks and...
Dr. Hui Zhou, Senior Vice President of Innovent, stated:"Given the clinically demonstrated benefits of taletrectinib in the TRUST-I trial, we are pleased to see the second NDA accepted by the NMPA of China. We wil...
The ORIENT-11 trial revealed that sintilimab + pemetrexed plus platinum could yield more survival benefits for patients with nonsquamous NSCLC. The present study aimed to assess the cost-effectiveness of sintilimab + pemetrexed plus platinum vs. that of pemetrexed plus platinum alone as the first...
randomized Phase III JAVELIN Bladder 100 trial established BAVENCIO first-line maintenance treatment following platinum-based chemotherapy as a standard of care, and long-term and real-world data such as these presented at ASCO GU 2023, continue adding to the evidence supporting its benefits for pati...
3, Dong Ding1, Shuosha Li1, Mengting Liao4, Yin Shi5 and Jin Huang1,6* Abstract Background: The clinical trial of Keynote-604 showed that pembrolizumab plus chemotherapy could generate clini- cal benefits for extensive-stage small-cell lung cancer (ES-SCLC)...